New insights into the efficacy of naltrexone based on trajectory-based reanalyses of two negative clinical trials.
about
Targeted opioid receptor antagonists in the treatment of alcohol use disordersTrajectory analyses in alcohol treatment researchPharmacological means of reducing human drug dependence: a selective and narrative review of the clinical literature.A cluster randomized controlled trial of an adolescent HIV prevention program among Bahamian youth: effect at 12 months post-intervention.Naltrexone and combined behavioral intervention effects on trajectories of drinking in the COMBINE study.Opioid modulators for alcohol dependence.BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP.Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study.Trajectories of depression severity in clinical trials of duloxetine: insights into antidepressant and placebo responses.The Effects of Naltrexone Among Alcohol Non-Abstainers: Results from the COMBINE Study.Baseline trajectories of heavy drinking and their effects on postrandomization drinking in the COMBINE Study: empirically derived predictors of drinking outcomes during treatment.A clinic-based motivational intervention improves condom use among subgroups of youth living with HIVCost-effectiveness of peer-delivered interventions for cocaine and alcohol abuse among women: a randomized controlled trialTreating alcoholism as a chronic disease: approaches to long-term continuing care.Continuing care research: what we have learned and where we are goingTreatment implications: using neuroscience to guide the development of new pharmacotherapies for alcoholism.Latent mixture models for multivariate and longitudinal outcomes.How to design PET experiments to study neurochemistry: application to alcoholism.Intramuscular extended-release naltrexone: current evidence.Naltrexone (50 mg) plus psychotherapy in alcohol-dependent patients: a meta-analysis of randomized controlled trials.Biodegradable In Situ Gel-Forming Controlled Drug Delivery System Based on Thermosensitive Poly(ε-caprolactone)-Poly(ethylene glycol)-Poly(ε-caprolactone) Hydrogel.Preparation and investigation of sustained drug delivery systems using an injectable, thermosensitive, in situ forming hydrogel composed of PLGA-PEG-PLGA.The effect of naltrexone on alcohol's stimulant properties and self-administration behavior in social drinkers: influence of gender and genotype.Open-label pilot study of injectable naltrexone for cannabis dependence.
P2860
Q28295125-A3C50077-8690-4BB9-889E-44063298C7E4Q30417809-69914B6E-6A37-4A51-8168-696BC769E1A0Q33582063-A31B73A9-1F9F-4387-84A8-9EFE8D141FE6Q33631911-E254908F-1E8F-4867-9B19-160668BE56C3Q33653182-B85F044E-0C14-4BC9-9FF6-D5D099EDFE5AQ34190543-08F20B01-A655-4F8A-8987-8306C0A9EB56Q34277168-2FE58FE2-843F-4866-9B31-58493D4A8D4CQ34622414-BDA0CD0E-3276-45D8-A9C1-FB4399ED22DAQ34634132-5F061AF5-5B34-41B2-B91D-FC7EEB16C3DBQ34689570-9AE56D37-2A13-4329-BBD5-41173AC40BCFQ35696834-5D9F50A3-6811-4BC7-ADE1-786EFB19E403Q35766088-775BF81F-7F21-45AF-9EED-BC0DA88BEF4DQ35842484-446AE9D0-0AD9-41B5-8BDF-09BD3C0C9B53Q36764731-A46D8FFB-0C13-453E-8016-ED0C31D5DDE3Q37162796-FE34492F-9570-42C6-B7BA-6591E5295986Q37386550-C22AA61F-73AE-42AB-961F-7BB3528C9687Q37553608-90B5BA1E-17C5-4050-8381-E6F4792928FBQ37615648-03F1F793-C087-41D9-84ED-CA3BC519A1A4Q37832752-F058AFE6-90BC-4EDC-9112-E10B3D8C8AC2Q38110618-ABE7536E-A3DF-4980-BEF8-B05430BC6AB0Q41821572-028DD538-D6A8-4521-9911-98C22E46480BQ41988316-7D8AA555-F371-420C-BBA3-E10F78402E10Q48147795-65417BA7-729B-4A34-A6DA-232906BAD861Q50107527-CC6D056E-C7AA-427B-828C-0A43ECEB54BD
P2860
New insights into the efficacy of naltrexone based on trajectory-based reanalyses of two negative clinical trials.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
New insights into the efficacy ...... two negative clinical trials.
@ast
New insights into the efficacy ...... two negative clinical trials.
@en
type
label
New insights into the efficacy ...... two negative clinical trials.
@ast
New insights into the efficacy ...... two negative clinical trials.
@en
prefLabel
New insights into the efficacy ...... two negative clinical trials.
@ast
New insights into the efficacy ...... two negative clinical trials.
@en
P2093
P2860
P1476
New insights into the efficacy ...... two negative clinical trials.
@en
P2093
Brian Pittman
John H Krystal
Joyce Cramer
Stephanie S O'malley
P2860
P304
P356
10.1016/J.BIOPSYCH.2006.09.038
P407
P577
2007-01-16T00:00:00Z